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Objective: To determine factors inﬂ  uencing the low return rate observed in a program of 
ﬂ  exible sigmoidoscopy for average risk screening for colorectal carcinoma.
Methods: Flexible sigmoidoscopy-based screening of average risk 55–64 yr olds has been 
ongoing since 1995. Greater than 3400 primary and 1000 follow up screening examinations have 
been performed. Participants with a primary screen in 1997–1999 and eligible for rescreening 
in 2002–2004 were studied. A questionnaire assessing possible reasons for noncompliance was 
sent to subjects who did not attend the ﬁ  ve year repeat screening.
Results: 1672 primary screening ﬂ  exible sigmoidoscopies were performed in 1997–1999 with 
1362 being normal or having hyperplastic polyps only. The return rate was 45%: 48% of eligible 
males and 39% of eligible females had returned (p = 0.001 for difference). 709 questionnaires 
were mailed with a 50% response rate and 162 requests for repeat ﬂ  exible sigmoidoscopy were 
generated. 27% of all respondents had undergone further bowel evaluation since the original 
normal sigmoidoscopy. Of eligible subjects who refused further screening, 65% did so because 
of concerns over procedural pain.
Conclusions: Reasons for nonattendance relate to uptake of other bowel investigations and pain 
felt at initial screening. Return rate can be raised with ongoing prompting to attend screening.
Keywords: sigmoidoscopy, colonoscopy, colonic neoplasm, population surveillance, patient 
compliance
Introduction
Five-yearly ﬂ  exible sigmoidoscopy (FS) is endorsed by many health authorities as 
an option for screening asymptomatic average risk individuals for colorectal cancer 
(Winawer et al 2001; Australian Cancer Network Colorectal Cancer Guidelines Revi-
sion Committee 2005). The effectiveness of this screening pathway will be inﬂ  uenced 
by participation rates for initial screening and subsequent follow up. This is particularly 
relevant for a screening modality that may only have a moderate sensitivity. Using the 
example of fecal occult blood testing (FOBT), a meta- analysis of randomized trials of 
FOBT reported an overall 16% mortality reduction from biennial screening but with 
a 23% reduction in those actually complying with screening (Towler et al 1998). In 
trials of ﬂ  exible sigmoidoscopy, widely varying initial participation rates have been 
reported, ranging from 15%–81% (Hoff et al 1985; Olynyk et al 1996; Verne et al 1998). 
Factors such as perceived lack of risk (either by lack of symptoms or family history), 
practical obstacles to undertaking the test, and fear or embarrassment regarding FS 
have been identiﬁ  ed as signiﬁ  cant barriers to attendance (Vernon 1997; McCaffery 
et al 2001). Concern about procedural pain or embarrassment may be more signiﬁ  -
cant for females compared to males (Weinberg et al 2004). Lack of interest or time 
is a commonly cited reason for nonattendance (Olynyk et al 1996). Additionally, in a 
randomly selected cohort, up to 30% of nonattendees were found to be ineligible for 
average risk screening (Olynyk et al 1996).Patient Preferences and Adherence 2008:2 28
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There is relatively little data examining the reasons for 
drop out of a program of serial ﬂ  exible sigmoidoscopy. 
A community based ﬂ  exible sigmoidoscopy screening pro-
gram has been in operation at Fremantle Hospital, Western 
Australia since 1995. Since inception, over 3400 screenings 
of average risk individuals have been performed and over 
1000 have returned for 5 year follow up, with an apparent 
return participation rate of 45% of eligible subjects. In this 
paper, we investigate the reasons why over half the subjects 
invited for repeat screening do not attend.
Methods
In 1995, a program of unsedated ﬂ  exible sigmoidoscopy-
based screening of asymptomatic average risk individuals 
aged 55–64 years was established at Fremantle Hospital. 
The project was conceived as a pilot study of this screening 
modality in Australia and was offered as a free service. At 
the time, no formal CRC screening program existed in the 
country and only recently has a national FOBT based pro-
gram commenced. In addition to FOBT, Australian national 
guidelines include ﬁ  ve-yearly FS as a screening option and 
the procedure can be accessed through public or private 
medical providers (Australian Cancer Network Colorectal 
Cancer Guidelines Revision Committee 2005).
Letters of invitation were sent to potentially eligible sub-
jects selected randomly from the Western Australian Electoral 
Roll. The cohort was drawn from postal codes in the geo-
graphic vicinity of the hospital. Participation from volunteers 
was also accepted. The methods and progress results of the 
screening program have been previously reported (Olynyk 
et al 1996; Collett et al 2000). In the program overall, 42% 
of participants have been volunteers for screening. Insertion 
depth of the exam and the self reported pain score has been 
prospectively recorded. The pain score was recorded follow-
ing the FS by use of a 0–10 point visual analogue scale (with 
a higher score reﬂ  ecting greater pain).
From the year 2000 onwards, ﬁ  ve-year recall of subjects 
with an initially normal (no polyps or hyperplastic polyps 
only) examination has been performed. Subjects were sent 
invitations for repeat ﬂ  exible sigmoidoscopy with a request 
to contact the program ofﬁ  ce to accept further screening. 
This letter is signed by the senior clinician in the program 
(JO) and outlines the beneﬁ  ts of repeat screening even if the 
original exam was normal or the subject is asymptomatic. 
The letter also asked about abdominal symptoms and family 
history of bowel cancer. People with symptoms or family 
history were advised to see their local general practitioner. 
At the time of phone contact, an interview is conducted to 
ascertain continued eligibility for screening. However, routine 
questioning regarding previous bowel investigations was not 
undertaken. Invitations for repeat FS were mailed to the last 
known address of participants as recorded in a dedicated 
database. If letters had been previously returned to sender, 
an effort was made to identify a new address by consult-
ing a centralized hospital encounters database or using any 
available forwarding address. Persons agreeing to further 
screening were allocated a booking for FS but this appoint-
ment could be up to six months later. Repeat procedures 
within the program have been performed by the same staff 
and methods as for the primary examination and were only 
offered at this institution
The set of persons who underwent primary screening in the 
years 1997–1999 and were apparently eligible for rescreening 
in 2002–2004 but did not return were selected as the study 
group. Screening participants from 1995–1996 were not 
chosen due to the length of time that has elapsed since their 
original examinations. Previous participants who were known 
to be deceased, had known interval colorectal cancer cases, 
those that had previously requested withdrawal from screening 
and subjects that had undergone colonoscopy at our institution 
(determined by reference to a hospital electronic endoscopy 
database) were excluded from the study. Additionally, central 
hospital databases were referenced to identify deceased indi-
viduals and to update all mailing addresses where possible.
The study group was assessed in two ways. Initially, 
univariate analysis of factors predicting attendance was per-
formed by chi-square testing for categorical variables and a 
logistic regression model was used to examine the effect of 
multiple categorical variables on future attendance of screen-
ing where a bivariate association with p  0.2 was observed. 
Comparison of results between groups was also done with 
t-tests. Data was analyzed using the Statistical Package for 
Social Sciences, version 11.0 (SPSS Inc, Chicago, Illinois). 
The variables considered were: gender, pain score recorded 
at original examination (score  3.0 or 3.0), proceduralist 
seniority (consultant or registrar/fellow), proceduralist train-
ing background (physician or surgeon) and insertion depth 
of the original examination.
Secondly, a short anonymous questionnaire was sent 
to those subjects identiﬁ  ed as nonattenders. Information 
was sought on reasons for nonattendance, listing a series 
of options which were broadly grouped as; lack of interest, 
lack of time, other bowel testing, health changes, and dis-
satisfaction with original examination. Where appropriate, 
the subject could enter additional information or select 
from a series of suboptions. A further section asked for the Patient Preferences and Adherence 2008:2 29
Compliance with serial screening ﬂ  exible sigmoidoscopy
individual’s opinion on how the screening procedure could 
be improved. Additionally, an option was given for the 
participant to request a new booking for follow up FS. All 
responses received were included in the analysis.
Results
Between 1997 and 1999, 1672 primary screening ﬂ  exible 
sigmoidoscopies were performed. A total of 1362 subjects 
were considered eligible for a recall examination and had 
been mailed an invitation to re-attend after 5 years. How-
ever, our review of medical records resulted in seventy seven 
individuals being excluded from the cohort: 12 known cancers 
(10 of these interval colorectal cancer), 32 deceased subjects, 
11 subjects having later colonoscopy at Fremantle Hospital 
and 22 cases were subjects having already notiﬁ  ed their 
intention to withdraw from the program (80% of these were 
because of new health problems that subjects felt superseded 
concerns regarding colorectal cancer). At the time of our study, 
513 subjects had undergone a second FS and 63 subjects were 
on a waiting list, yielding an apparent return rate for 5 year 
follow-up of 576/1285 (45%) for eligible persons. A ﬂ  owchart 
of patient recruitment into the survey is shown in Figure 1.
Total screenings for 
1997-1999 
1672 
Recommendation for 
colonoscopy or other 
follow up 
310 
Normal or hyperplastic polyp at 
flexible sigmoidoscopy 
1362 
Attended or awaiting 
5-year follow up 
576 
No record of 
repeat FS 
709 
Withdrawn from or 
ineligible for screening 
77
•  Identified 
cancers:12 
•  Identified 
deaths:32 
•  Known interval 
colonoscopy:11
•  Previously
withdrawn from 
screening:22 
Assumed correct 
address on database
562
Possible new 
address detected 
147 
Return to 
sender 
44 
Return to 
sender 
6
Survey 
response 
88 
Survey 
response 
265
Figure 1 Flowchart of patient recruitment into the survey.Patient Preferences and Adherence 2008:2 30
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Review of the screening database prior to the current 
study indicated that 48% of apparently eligible males and 
39% of eligible females returned for follow-up screening 
(p = 0.001 for difference between genders). The mean 
pain score reported for the primary exam was 3.1 for all 
those attending follow-up screening compared with 4.0 for 
those not attending follow-up (p  0.0001). On univariate 
analysis, female gender, pain score more than 3.0, procedure 
performed by a fellow and insertion depth of less than 50 cm 
were associated with a reduced likelihood of return (p  0.2). 
The training background of the initial proceduralist did not 
appear signiﬁ  cant. Female sex (OR 0.8, 95% CI 0.6–0.9), pain 
score more than 3.0 (OR 0.7, 95% CI 0.6–0.9) and insertion 
depth less than 50 cm (OR 0.7, 95% CI 0.5–0.9) remained 
as independent predictors of future nonattendance following 
logistic regression analysis.
After exclusions, 709 nonattending subjects (51% male) 
remained eligible for our study: 562 of whom had the same 
current mailing address whilst 147 had a new address found. 
Three hundred and ﬁ  fty three responses were received (50% 
response rate) with an additional 50 letters returned to sender. 
Fifty two percent of respondents were female. One hundred 
and sixty two respondents requested a new booking for FS 
and were considered eligible to continue in the screening 
program.
Of 353 respondents, 94 (27%) reported having further 
bowel evaluation in the time since their original FS (Figure 2). 
Forty three percent indicated that this was because of new 
bowel symptoms and 8% because of a new family history 
of CRC, although almost half of respondents did not give a 
speciﬁ  c reason. Colonoscopy was the investigation performed 
in at least 48 cases though once again, many did not specify 
the investigation performed in their response.
Ninety seven (28%) of the 353 respondents deﬁ  nitely 
declined further participation in FS screening and had not 
undergone any other interval bowel evaluation. When asked 
to provide reasons for this decision, 65% cited the pain or 
unpleasantness of FS as a key determinant (Figure 2) with a 
All respondents 
353 
Eligible for rescreening
and requested a new 
appointment be made 
162 
Reported other bowel 
evaluation since screening
94 
New symptoms: 43 
New family history: 8 
Not specified: 43 
Colonoscopy was 
performed in at least 48 
cases 
No other interval bowel 
testing but declined further 
screening 
97  
No time to attend: 8% 
No interest: 18% 
Change to health: 9% 
Procedure was painful or 
unpleasant: 65% 
Moved away: 2% 
Other: 16% 
Figure 2 All respondents’ reasons for no further attendance of serial ﬂ  exible sigmoidoscopy.Patient Preferences and Adherence 2008:2 31
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similar proportion of males and females giving this response. 
Lack of interest or lack of time was a less frequent reason. 
Nine percent listed a major health change with examples of 
malignancy or cerebrovascular disease being cited. Other 
reasons provided included feelings of embarrassment, per-
ceptions of inexperienced or uncaring staff and poor com-
munication of results following the procedure.
Respondents were asked to comment on ways to 
improve the experience they had of FS screening and 153 
gave a response. Not surprisingly, 139 (91%) indicated that 
measures to reduce pain were required. More ﬂ  exibility of 
appointment times (9%), less time in hospital on the day 
(8%) and less delay to appointment dates (3%) were also 
selected. A number of respondents wrote that they would 
elect to receive anesthesia at their next FS, indicating some 
failure on the program’s part to communicate the nature of 
the screening procedure adequately.
Discussion
Flexible sigmoidoscopy every 5 years is recommended as an 
option for screening average risk individuals for colorectal 
cancer although screening trials are currently investigating 
the impact of once only screening FS (Segnan et al 2002; UK 
Flexible Sigmoidoscopy Screening Trial Investigators 2002). 
Our program has previously reported that 10% and 2% of 
repeat examinations ﬁ  nd neoplasia and advanced neoplasia, 
respectively (Viiala et al 2007). Although the uptake of FS in 
trials is variable, experience suggests that participants ﬁ  nd it 
an acceptable procedure and the majority of subjects indicate 
willingness to undergo the procedure again (Nicholson and 
Korman 2005). Within our own program, 94% of subjects 
having an initial FS would have the procedure again (Collett 
et al 2000). However, the actual return rate of 45% we have 
experienced in our program implies that other factors develop 
over time to reduce participation.
An important ﬁ  nding is that over time, a substantial 
proportion of subjects change address or may be temporarily 
absent and do not receive and respond to mailed invitations. 
Our study found that by offering the option of repeat exami-
nation with the questionnaire, we were able to generate 162 
bookings for follow up from 709 mail outs. This in itself would 
theoretically lift the overall return rate from 45% to 57%. 
While we had relied on being notiﬁ  ed of change of address by 
program participants, it is clear that a formal screening pro-
gram requires a mechanism of tracking address changes more 
effectively, such as by linkage to an electoral roll. The fact 
that we received 50 returned letters from incorrect addresses 
even after using hospital databases supports this.
Another ﬁ  nding of signiﬁ  cance is the relatively high 
dropout rate due to uptake of other bowel examinations, 
with 94/353 (27%) of respondents reporting further bowel 
investigation since their original FS. In many, this was due 
to the development of new symptoms or new family history 
of CRC and colonoscopy appears to be the investigation 
of choice. Signiﬁ  cant self-rated changes to health, such as 
stroke or malignancies were reported in 9/97 cases of those 
who appeared eligible for further screening but declined to 
have it. It may not be accurate to extrapolate these ﬁ  ndings 
to the entire cohort given our 50% response rate, but at the 
very least, some 13% of the original screening group have 
died or become ineligible to continue as average risk CRC 
screening in the interval between 5-yearly FS. If we do 
assume that similar frequencies of health changes occurred 
in those who did not reply to our questionnaire and if the new 
screening requests (n = 162) generated by the questionnaire 
are included, and the potential number of medical exclu-
sions are considered, it is conceivable that up to 21% of the 
original participants become ineligible for further “average 
risk” screening at 5 years. As such, the true participation rate 
of eligible subjects in ongoing FS screening rises from the 
observed 45% rate to 68%. This compares favorably with 
FOBT trials that report compliance rates with later rounds of 
screening in the order of 50%–60% (Hardcastle et al 1996; 
Kronborg et al 1996; Mandel et al 1999; Faivre et al 2004).
Analysis of pain score data prior to sending the ques-
tionnaire had suggested that the discomfort of FS would be 
a major determinant of further attendance and that females 
would be less likely to return. In studies of primary screening 
by sigmoidoscopy or colonoscopy there has been an indica-
tion that women are less likely to attend, despite a large body 
of literature showing that females are more likely to undertake 
preventative health measures in general (Senore et al 1996; 
Seeff et al 2004). A number of studies have reported that 
females invited for ﬂ  exible sigmoidoscopy had a number 
of perceived barriers to screening including anticipation of 
greater discomfort and embarrassment from the procedure 
than males (Farraye et al 2004; Wardle et al 2005). Addition-
ally, women report a preference for a female proceduralist 
(Farraye et al 2004; Menees et al 2005).
It is not surprising that for those subjects declining fur-
ther screening, FS-related pain was a major determinant in 
65% of cases overall, with similar responses from females 
and males. For both sexes, the main modiﬁ  able risk factor 
for nonattendance clearly seems to be concern over a pain-
ful procedure. Ensuring the initial FS is not distressing will 
promote compliance with later follow up. Other factors that Patient Preferences and Adherence 2008:2 32
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might affect attendance at screening, such as wait-time for 
an appointment or ﬂ  exibility with screening times were not 
rated as very important by most respondents. Studies have 
addressed pain reduction techniques such as distraction 
(Lembo et al 1998), different calibre endoscopes (Farraye 
et al 2004) and medications such as inhaled nitrous oxide 
(Fich et al 1997), sublingual hyoscine (Dumot et al 1998) 
or oral midazolam (Kuganeswaran et al 1999). There is an 
issue with over-complicating the procedure, particularly by 
introducing sedation thereby reducing any advantages of a 
FS compared to colonoscopy for large scale screening. An 
obvious strategy would be to direct such individuals to an 
alternate screening strategy if initial sigmoidoscopy proves 
limited or excessively painful. Inadequate screening of 
subjects is associated with an increased risk of colorectal 
cancer compared with those who undergo adequate examina-
tion (Doria-Rose et al 2005).
Our study has sought to examine reasons why people are 
not compliant with serial ﬂ  exible sigmoidoscopy. The conclu-
sions we have drawn are based on the answers from the 50% 
of subjects who responded to the questionnaire and may not 
be representative of the whole group. We chose to use anony-
mous questionnaires in an attempt to maximize the response 
to the research although this somewhat limited our analysis 
of results. We were not able to collect detailed information 
about the nature of new health problems or the reasons why 
individuals underwent other bowel investigations and so it is 
not certain that all these individuals had become ineligible 
for average-risk screening. Additionally, we are not able to 
distinguish between those who were originally volunteers for 
screening compared to invited for screening and determine 
how the act of volunteering affects future compliance.
In conclusion, our study suggests that the participation 
rate for serial FS can be substantially improved by accurate 
tracking of address changes and by repeated mail outs to 
prompt attendance. In fact, failure to track program partici-
pants after their initial examination appears to be the single 
most important factor affecting attendance at ﬁ  ve year follow 
up. The compliance rate with 5-yearly ﬂ  exible sigmoidos-
copy screening has not been previously well documented 
and our study shows that at least 13% of eligible subjects 
may drop out over time due to health changes or uptake of 
other bowel investigations. Concern over procedural pain 
was also a major issue contributing to nonattendance for 
follow-up screening FS for both genders. Measures that 
promote attendance at ﬁ  rst sigmoidoscopy and minimize 
the discomfort of the test are likely to increase compliance 
with future screening.
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